All In Biotech

Drug Trial Radar · NCT04893577

EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions

A Randomized, Efficacy Assessor-Blinded, Study to Assess Preliminary Efficacy and Safety of EDTA Eye Drops v. an Active Comparator in the Suppression of Herpes Simplex Virus Eruptions in Subjects With a History of Herpes Labialis

Last checked: Nov 20, 2026Latest source record: Oct 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jan 20, 2022

Primary completion

Aug 31, 2024

Study completion Aug 1, 2025

Sponsor

Lead sponsor
University of UtahAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis. Patients will be treated with the study drug, EDTA Eye Drops or the active comparator of Abreva. Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, subjects that meet all other entry criteria will undergo UV susceptibility testing to determine their individual MED (minimal erythemal dose). UV susceptibility testing takes place over two days with exposure to UV light on specified regions on the subject's back followed by an assessment of the exposed areas 24 hours later to identify the MED. Subjects who have a measurable MED will be allowed to enroll in the study. Each subject will be randomly assigned in a 1:1 ratio to receive either EED or Comparator. Patients who express a cold sore will track the lesion with a diary card to rate their pain levels, and any unusual symptoms at Day 1, Day 3, Day 5, Day 7, and Day 10. Patients may also take photographs of the lesion throughout the study.

Conditions

  • Herpes Simplex Oral

Interventions

  • EDTADrug

    Patients will treat their cold sore with EDTA eye drops based upon their randomization.

  • AbrevaDrug

    Patients will treat their cold sore with Abreva based upon their randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration (Days) of Herpes Labialis Outbreak Until HealedTime frame: Up to 14 days per patient

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Utah MidValley Dermatology

    Murray, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.